vimarsana.com
Home
Live Updates
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows : comparemela.com
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
KR-HT5 is based on Akoya’s PhenoImager® HT PlatformMARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 -- Akoya Biosciences, Inc. , The Spatial Biology Company®, and Shanghai KR Pharmtech, a...
Related Keywords
China ,
Shanghai ,
Xuzhou ,
Jiangsu ,
Chinese ,
Akoya Biosciences ,
Brian Mckelligon ,
Rui Zhang ,
Akoya Bioscience ,
Priyam Shah ,
Akoya Phenoimager ,
Spatial Biology Company ,
Medicine Technology Research ,
Nasdaq ,
Exchange Commission ,
China National Medical Products Administration ,
Akoya Biosciences Inc ,
Spatial Biology ,
National Medical Products Administration ,
Multispectral Imaging ,
Next Generation Pathology ,
Financial Condition ,
Smart Medical Industry ,
Next Generation Sequencing ,
Investor Contact ,
Media Contact ,
Markets ,
comparemela.com © 2020. All Rights Reserved.